文献速递肺结节与肺癌

低剂量CT肺癌筛查获益时间分析

Timing of Screening Benefit for Lung Cancer With Low-Dose CT Imaging.
PubMed 文献 · Chest · 2025-06-18

该研究基于4项随机对照试验共64,105名高危个体,采用既定分析框架估算低剂量CT筛查的获益时间。NLST中每2000人筛查1.78年可预防1例肺癌死亡,每1000、500、200人筛查預防1例死亡分别需2.87、4.66、8.87年。结论提示预期寿命有限者可能不适合LDCT筛查。

要点

  • 每2000人筛查1.78年可预防1例肺癌死亡。
  • 每1000、500、200人筛查预防1例死亡需2.87、4.66、8.87年。
  • 预期寿命有限者可能无法从LDCT筛查获益。

核心结论

  • LDCT筛查的临床获益可能不适合预期寿命有限的个体。
  • 将获益时间估计纳入患者选择标准有助于最大化LDCT筛查获益。

研究设计与样本

  • 系统检索PubMed中低剂量CT肺癌筛查并报告死亡率结局的群体随机对照试验。
  • 采用既定分析框架对NLST和4项试验的汇总数据估算获益时间。
  • 分析纳入4项试验共64,105名个体,NLST样本量为53,452。

主要发现

  • NLST中每2000人筛查1.78年(95%CI 0.60-5.27)可预防1例肺癌死亡。
  • 每1000人筛查平均需2.87年(95%CI 1.31-6.32)预防1例肺癌死亡。
  • 每500人筛查平均需4.66年(95%CI 2.64-8.21)预防1例肺癌死亡。
  • 每200人筛查平均需8.87年(95%CI 5.12-15.37)预防1例肺癌死亡。
  • 加入其他试验后上述结果未见变化。

临床怎么用

  • 对预期寿命有限的高危个体,应结合获益时间估计评估LDCT筛查的适宜性。
  • 可将获益时间估计整合入患者选择标准以优化LDCT筛查的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing evidence supports lung cancer screening with low-dose CT (LDCT) imaging. However, the benefits of LDCT screening for lung cancer may not be immediate, making it unlikely to benefit patients with limited life expectancy. RESEARCH QUESTION: What is the time to benefit (TTB) from LDCT screening for individuals at high risk for lung cancer? STUDY DESIGN AND METHODS: Population-based randomized controlled trials of lung cancer screening using LDCT imaging and reporting mortality outcomes were systematically searched in PubMed. TTB was estimated for the National Lung Screening Trial (NLST) and the pooled data from 4 trials using an established analysis framework. RESULTS: This analysis included 4 trials encompassing 64,105 individuals. In the NLST (N = 53,452), to prevent 1 death from lung cancer, 2,000 individuals would need to be screened over 1.78 (95% CI, 0.60-5.27) years. On average, it took 2.87 (95% CI, 1.31-6.32), 4.66 (95% CI, 2.64-8.21), and 8.87 (95% CI, 5.12-15.37) years before 1 death from lung cancer was prevented for every 1,000, 500, and 200 individuals screened, respectively. These findings did not vary when added to other trials. INTERPRETATION: Our findings suggest that the clinical benefits of LDCT screening may not be appropriate for individuals with limited life expectancy. Integrating TTB estimates into patient selection criteria could help maximize the benefits of LDCT screening.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Xie Y, Zhang Y, Zhang P, et al. Timing of Screening Benefit for Lung Cancer With Low-Dose CT Imaging. Chest. 2025. PMID: 40541736. doi:10.1016/j.chest.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。